The graft comes out of your DRG, not the insurer’s

One major payer names us favourably. Two do not.

Humana covers calcium phosphate ceramics and names ACTIFUSE, while excluding beta-TCP and bioactive glass. UnitedHealthcare calls all ceramics unproven. Aetna calls ACTIFUSE experimental. Anyone selling you a coverage advantage is quoting one policy and hiding two.

It matters less than it looks: inpatient, everything is bundled anyway, and UHC’s favourable InFUSE lane is the narrow on-label one while roughly 85% of real BMP-2 use sits outside it. The decision is what it always was: your cost, your nonunion risk, your call.

93% pooled fusion, equivalence to rhBMP-2, caveats included

Cottrill 2020, Johns Hopkins, independent, 694 patients: 93% fusion, no significant difference vs rhBMP-2, standalone equivalent to mixed. Coughlan 2018, randomized, Baxter funded and disclosed: equivalent fusion, lower back-pain scores, significant at six months.

What it does not show: superiority to rhBMP-2 or other synthetics. The pooled data is heterogeneous and the authors say so. We hand your reviewer that list first, because they will find it anyway.

Send us your payer mix and graft spend per fusion

We return current policy pulls for your actual payers, including the ones against us, and the nonunion math on your numbers. No charge, no obligation. If it holds up, we cover the first cases in your OR and in-service your staff.